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Macrophages (M8s) are critical regulators of immune response and serve as a link
between innate and acquired immunity. The precise mechanism of involvement of
tissue-resident M8s in the pathogenesis of autoimmune diseases is not clear. Here, using
a murine model for Sjögren’s syndrome (SS), we investigated the role of tissue-resident
M8s in the onset and development of autoimmunity. Two unique populations of
CD11bhigh and CD11blow resident M8s were observed in the target tissue of the
SS model. Comprehensive gene expression analysis of chemokines revealed effective
production of CCL22 by the CD11bhigh M8s. CCL22 upregulated the migratory
activity of CD4+ T cells by increasing CCR4, a receptor of CCL22, on T cells in
the SS model. In addition, CCL22 enhanced IFN-γ production of T cells of the SS
model, thereby suggesting that CCL22 may impair the local immune tolerance in
the target organ of the SS model. Moreover, administration of anti-CCL22 antibody
suppressed autoimmune lesions in the SS model. Finally, histopathological analysis
revealed numerous CCL22-producing M8s in the minor salivary gland tissue specimens
of the SS patients. CCL22-producing tissue-resident M8s may control autoimmune
lesions by enhancing T cell response in the SS model. These results suggest that specific
chemokines and their receptors may serve as novel therapeutic or diagnostic targets for
SS.
Keywords: autoimmunity, tissue-resident macrophage, chemokine, salivary gland, Sjögren’s syndrome, T cell
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INTRODUCTION
Macrophages (M8s) differentiate from bone marrow-derived monocytes or tissue-resident cells
derived from yolk sac or fetal liver. These cells tend to exhibit distinct tissue-specific phenotypes,
such as histiocytes in connective tissues, Kupffer cells in the liver, microglia in the central nervous
system and various specialized macrophages in the alveolar, peritoneal, and synovial tissues (1, 2).
Tissue-resident M8s represent a vital component of the innate immunity system and function as
phagocytic cells that engulf and digest cellular debris, foreign substances, microbes, and pathogens
(3). They also secrete cytokines and chemokines that modulate the activities of other immune cells
in inflammatory lesions (3). Besides phagocytosis and immune signaling, in conjunction with DCs,
M8s present antigens to T cells: this acts as a link between innate and acquired immunity (3).
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M8s also contribute to the recovery or remodeling of injured
tissues via promotion of angiogenesis or fibrosis (4, 5).
However, the multilateral roles of tissue-resident M8s in various
inflammatory disorders are unclear.
Classically activated (M1) M8s produce pro-inflammatory
cytokines, such as interleukin (IL)-1β, interferon (IFN)-γ, and
tumor necrosis factor (TNF)-α (1, 6). Alternatively activated
(M2) M8s produce anti-inflammatory cytokines, such as IL-10
and IL-4, with a specific profile that depends on the M2 M8
subset (M2a, b, and c) (1, 7). M8s are involved in inflammatory
tissue damage associated with autoimmune response (8). In
addition, M8s also support tissue repair and restoration of
immune homeostasis (9, 10). Thus, M8s play a key role in
various physiological and pathological responses as classically
activated M8s, wound-healing M8s, and regulatory M8s.
Although tissue-resident M8s are also considered as immune
cells and have a variety of functions, the precise role of tissue-
resident M8s in autoimmune response is obscure.
Sjögren’s syndrome (SS) is a chronic autoimmune disease
that affects exocrine glands, such as salivary and lacrimal
glands; SS also causes systemic autoimmune lesions (11, 12).
A variety of mononuclear cell populations that infiltrate the
salivary gland tissues were observed in patients with SS (13, 14).
Among these, infiltration of T cells, B cells, DCs, and M8s is
correlated with lesion severity (15). SS is triggered by T cell-
mediated autoimmune response; however, other immune cells
also contribute to the onset or development of SS, including
M8s (16–18). M8s are observed in the autoimmune lesions of
salivary gland tissues of patients with SS (19). Moreover, elevated
expression of M8-derived molecules, such as chitinase-3-like
protein 1 and chitinase 1, is associated with increased severity
of SS lesions, thereby indicating the involvement of M8 in
the pathogenesis of SS (20). Furthermore, several chemokines
secreted from M8s in the salivary glands of patients and animal
models with SS contribute to the onset or development of SS
(21, 22). However, the molecular or cellular mechanism of the
pathogenesis of SS through the tissue-resident M8s in the target
organ has not been defined.
Here, using a mouse model of SS, we investigated the
association of resident M8s in the target organs of SS with the
onset and development of autoimmune lesions. In particular, we
evaluated the precise contribution of M8s to T cell response in
a SS model and patients with SS. The findings of the current
study may help us comprehend a novel pathogenic mechanism




Female NFS/N mice carrying the mutant sld were bred and
maintained in a specific pathogen-free mouse colony in the
animal facility at Tokushima University (Tokushima, Japan).
Neonatal thymectomy was performed on day 3 after birth to
generate the SS model mice. Control mice used in this study
were sham (non)-thymectomized NFS/sld mice that exhibit no
inflammatory lesions in the salivary and lacrimal glands. In
addition, we confirmed that the phenotypes and functions of
immune cells of control mice showed no abnormality, compared
with those of age- and sex-matched C57BL/6 mice. This study
was conducted according to the Fundamental Guidelines for
Proper Conduct of Animal Experiment and Related Activities
in Academic Research Institutions under the jurisdiction of the
Ministry of Education, Culture, Sports, Science and Technology
of Japan. The protocol was approved by the Committee on
Animal Experiments of Tokushima University and Biological
Safety Research Center, Japan (Permit Number: T-27-7). All
experiments were performed after administration of anesthesia,
and all efforts were made to minimize suffering.
Cell Isolation
For the isolation of M8 from the salivary gland, bilateral
whole salivary gland lobes were minced into 1–3mm pieces and
were digested with collagenase (1 mg/mL, Wako), hyarulonidase
(1 mg/mL, SIGMA-ALDRICH), and DNase (10 ng/mL, Roche)
in Dulbecco’s modified Eagle’s medium (DMEM) containing
10% fetal calf serum at 37◦C for 40min using gentleMACS
Dissociators (Miltenyi Biotec). Subsequently, mononuclear cells
were enriched using a Histopaque-1083 (Merck) from a single-
cell suspension of salivary gland tissue. Mononuclear cells
were labeled with anti-CD45.2, F4/80, CD11b, CD3, and CD19
antibodies (eBioscience); subsequently, CD11bhigh F4/80+ M8s
and CD11blow F4/80+ M8s were isolated using a cell sorter
(JSAN JR Swift, Bay Bioscience). Splenocytes and cervical lymph
node (cLN) cells were homogenated in DMEM containing 2%
FBS using gentleMACS Dissociators (Miltenyi Biotec). Using
0.83% ammonium chloride, red blood cells were removed from
the spleen cells. Splenic CD4+ T cells were obtained by negative
selection using the EasySep mouse CD4+ T cell Isolation Kit
(STEMCELL Technologies). Flow cytometric analysis showed
that CD4+ cells accounted for >90% of the isolated cells.
In addition, the viability of the isolated cells was checked
by cell counter (CYTORECON, GE Healthcare) using trypan
blue staining. The cell number was determined as the total
absolute number of lymphocytes per each organ by cell counter
(CYTORECON) using trypan blue staining; subsequently, the
proportion of the suspended cells was analyzed by flow
cytometry. The absolute number of T cells or macrophages was
calculated using the data pertaining to total cell number and
the proportion. As for the salivary gland, we used bilateral lobes
to determine the cell number and the proportion of immune
cells. As for splenocytes and cervical lymph node cells, the whole
spleen and bilateral cervical lymph nodes per mouse were used to
determine the cell number and the proportion.
Flow Cytometric Analysis
Immune cells were stained using antibodies against FITC-
conjugated anti-mouse CD206 (BioLegend, C068C2) and CD11c
(eBioscience, N418) mAbs, PE-conjugated anti-mouse MHC
class II (Miltenyi Biotec, REA478), CD86 (BD Bioscience,
GL1), CD204 (eBioscience, M204PA), CCR2, CX3CR1, CCR4
(BioLegend, SA203G11, SA011F11, and 2G12), PE-Cy5.5-
conjugated anti-mouse CD3 and CD19 (TONBO Biosciences,
145-2C11, and 6D5) and 7-Aminoactinomycin D (7-AAD)
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staining solution (TOMBO Biosciences), PE-Cy7-conjugated
anti-mouse CD11b (TONBO Biosciences, M1/70), APC-
conjugated anti-mouse F4/80 and CD36 (BioLegend, BM8
and HM36), and APC-Cy7-conjugated anti-mouse CD45.2
(TOMBO, 104) mAbs. For detecting intracellular CCL22
expression, rabbit anti-CCL22/MDC (abcam, rabbit monoclonal
IgG, EPR1362) Ab, and Alexa Fluor 568 goat anti-rabbit IgG
(Invitrogen) were used. A FACScant flow cytometer (BD
Biosciences) was used to identify the cell populations according
to expression profile. Viable cells were checked by gating on
side scatter (SSC)/forward scatter (FSC), FSC-H/FSC-A, 7AAD,
CD45.2, and CD4. We used 5×105 cells as a sample for the
analysis. Data were analyzed using the FlowJo FACS Analysis
software (Tree Star Inc.).
Phagocytosis Assay
Phagocytosis was assessed for using the Phagocytosis Assay Kit
(IgG FITC, Cayman Chemical). Mononuclear cells from the
salivary glands provided as previously described were cultured
in DMEM containing 10% FBS at 37◦C and were washed with
PBS 24 h later to remove unbounded cells. Adherent cells were
incubated with the opsonized beads for 2 h at 37◦C or at 4◦C for
controls; this was followed by washing with PBS. The phagocytic
activity of F4/80+ CD11bhigh and F4/80+ CD11blow M8s was
analyzed using flow cytometry.
RNA Extraction
Total RNA was isolated from the purified macrophages and
cultured cells using the RNeasy Plus Mini Kit (Qiagen) with
a gDNA eliminator column treatment step. Total RNA was
extracted from the salivary glands, lung, spleen, and liver tissues
using Isogen (FUJIFILM Wako Pure Chemical). Total RNA was
then reverse-transcribed into cDNA using the PrimeScript II




Expression levels of mRNAs encoding CCL22, CCR4, IFN-γ, IL-
4, IL-17, and β-actin were determined using a 7300 real time
PCR system (Applied Biosystems) with TB Green Premix Ex Taq
II (Takara Bio). PCR was performed followed by 40 cycles for
10s at 95◦C and for 15 s at 60◦C. The primer sequences used
were as follows: CCL22: forward, 5′-TCATGGCTACCCTGC
GTGTC-3′, and reverse, 5′-CCTTCACTAAACGTGGCAGAG-
3′, CCR4: forward, 5′-GGCTACTACGCCGCCGAC-3′, and
reverse, 5′-TACCAAAACAGCATGATGCC-3′, IFN-γ: forward,
5′-AGCGGCTGACTGAACTCAGATTGTA-3′, and reverse, 5′-
GTCACAGTTTTCAGCTGTATAGGG-3′, IL-4: forward, 5′-
TCTCATGGAGCTGCAGAGACTCT-3′, and reverse, 5′-TCC
AGGAAGTCTTTCAGTGATGTG-3′, IL-17: forward, 5′-AGT
GTTTCCTCTACCCAGCAC-3′, and reverse, 5′-GAAAACCGC
CACCGCTTAC-3′, β-actin: forward, 5′-GTGGGCCGCTCT
AGGCACCA-3′, and reverse, 5′-CGGTTGGCCTTAGGGTTC
AGGGGG-3′. Relative mRNA expression of each transcript was
normalized against β-actin mRNA.
Histological Analysis
Salivary gland tissues were fixed with 10% phosphate-buffered
formaldehyde (pH 7.2), and were prepared for histological
examination. Sections (4µm) were stained with hematoxylin and
eosin (H&E).
Immunohistochemistry
Tissue sections (6µm) were deparaffinized in xylenes and were
rehydrated by passage through serial dilutions of ethanol in
distilled water. Heat-induced antigen retrieval was performed
in Immunoactive (Matsunami Glass Ind. Ltd) with microwave
thrice for 5min. Anti-mouse F4/80 antibody (eBioscience),
anti-human CCL22 (abcam), and anti-mouse CCL22 (abcam)
antibody were applied to the sections; the sections were then
incubated overnight at 4◦C. After washing with PBS, the
sections were incubated with biotinylated second antibody and
horseradish peroxidase (HRP)-conjugated streptavidin solution
(DAKO). HRP reacted with the 3,3′-diaminobenzidine (DAB)
substrate using the Histofine DAB substrate kit (Nichirei
Biosciences Inc.). The sections were counterstained with
hematoxylin.
Confocal Analysis
Frozen sections (6µm) of salivary gland tissues were fixed with
cold acetone, blocked with 10% goat serum (DAKO), and then
stained with a rabbit monoclonal antibody against CCL22/MDC
(abcam), FITC-conjugated anti-mouse F4/80 (BioRad), rat
monoclonal antibody against anti-EpCAM (eBioscience, G8.8),
anti-CD3 (eBioscience, 1.45-2C11), anti-CD19 (eBioscience,
eBio1D3), and biotinylated anti-CD11c (Biolegend, N418)
antibodies. After washing with PBS, Alexa Fluor 568-conjugated
anti-rabbit IgG (Invitrogen) and Alexa Fluor 488-conjugated
anti-fluorescein Green goat IgG fraction (Invitrogen), or
Alexa Fluor 488-conjugated anti-rat IgG (Invitrogen), or
Alexa Fluor 488-conjugated streptavidin (Invitrogen) were
used as secondary antibodies. Nuclear DNA was stained
with 4′,6-Diamdino-2-phenylindole dihydrochloride (DAPI)
(Invitrogen). In addition, the paraffin-embedded sections from
SS patients and controls were stained with anti-CD68 (DAKO,
Klon EBM11), anti-Keratin (DAKO, AE1/AE3), anti-CD3
(DAKO, F7.2.38), anti-CD19 (DAKO, LE-CD19), anti-S100
(abcam, 4C4.9), and anti-CCL22 Abs (abcam). The sections
were examined using a PASCAL confocal laser-scanning
microscope (LSM: Carl Zeiss) at 400× magnification. LSM
image browser version 3.5 (Carl Zeiss) was used for image
acquisition.
Gene-Expression Analysis With PCR Array
Chemokine-related gene expression of sorted CD11blow and
CD11bhigh sM8s were analyzed using PCR array. Total RNA
was reverse-transcribed to cDNAs using the RT2 First Strand
Kit (Qiagen). The cDNA was applied to RT2 Profiler PCR
array (PAMM-022ZE-1) plates to detect the expression of
genes related to chemokines. Real-time PCR reactions were
performed on a 7900HT Real-Time PCR System. (Applied
Biosystems). Raw data were extracted and analyzed according
to the Qiagen RT2 Profiler PCR Array Data Analysis web
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portal. Gene expression levels were calculated using the 11Ct
method; the relative gene expression levels were normalized
using four house-keeping genes (Actb, B2m, Gapdh, and
Gusb).
Chemotactic Migration Assay and in vitro
Culture of CD4+ T Cell With CCL22
Splenic CD4+ T cell were cultured for 5 days in RPMI
1640 containing 10% FBS with Dynabeads mouse T-activator
CD3/CD28 (Invitrogen) at bead/cells ratio of 1:1 and 30 U/mL
of rIL-2 (eBioscience). After serum starvation in RPMI 1640
medium for 3 h , splenic CD4+ T cells were seeded (1.0 × 106
cells in 400 µL) in Millicell Culture Plates Inserts (5.0-µm pore
size,MerckMillipore). 600µl of RPMI 1640 containing 0.1%BSA
containing CCL22 (200 ng/mL; R&D Systems Inc.) was added to
the lower chamber. The cells were cultured for 3 h at 37◦C and
then the numbers of migrated cells were counted by cell counter
(CYTORECON, GE Healthcare UK).
CD4+ T cells purified from the spleen, cLNs, and salivary
glands in SS model mice were cultured with CCL22 for 6 h. Then
the mRNA of the T cells was purified for analysis of cytokine gene
expression.
Analysis of Intracellular Cytokine
Expression
CD4+ T cells (1 × 106/well) isolated form spleen of control and
SS model mice, or T cells (2 × 105/well) isolated form salivary
gland tissues of SS model mice were stimulated with Dynabeads
mouse T-activator CD3/CD28 (Invitrogen) at bead/cell ratio of
1:4 and CCL22 (200 ng/mL) for 48 h, and were then cultured
with phorbol myristate acetate (PMA; 50 ng/mL, Sigma-Aldrich,
St. Louis, MO) and ionomycin (IM; 1µg/mL, Sigma-Aldrich)
in the presence of Brefeldin A (eBioscience) for the last 6 h.
After washing, cells were stained with an anti-CD4 mAb, fixed in
fixation/permeabilization solution (eBioscience); permeabilized
in permeabilization buffer (eBioscience); and stained with anti-
IFN-γ (eBioscience, XMC1.2), IL-4 (TONBO, 11B11), and IL-
17A (eBioscience, TC11-18H10.1).
Analysis of Cytokine Levels
CD4+ T cells isolated from salivary gland tissues of SS model
mice were cultured with or without CCL22 (200 ng/mL) in
the presence of Dynabeads mouse T-activator CD3/CD28
(Invitrogen) at bead/cell ratio of 1:4 for 48 h and subsequently
cultured with PMA (50 ng/mL, Sigma-Aldrich) and IM
(1µg/mL, Sigma-Aldrich) for the last 6 h. Cytokine levels,
including IFN-γ, IL-4, and IL-17, in the supernatant were
measured using a Cytokine 20-Plex Mouse Panel Luminex assay
kit (Invitrogen) according to the manufacturer’s instructions.
Administration of Anti-CCL22 Antibody
Four µg of goat anti-CCL22 polyclonal Ab (R&D System) or
control polyclonal goat IgG Ab (Santa Cruz Biotechnology, sc-
3887) was intravenously injected into the SS model mice aged 8
weeks on alternate days for 2 weeks. The mice were examined at
10 weeks of age.
Human Subjects
This study was approved by the Institutional Review Board of the
Tokushima University Hospital, Japan (No. 2802). All patients
with SS were diagnosed according the criteria for diagnosis
of SS by the Japanese Ministry of Health and the American
College of Rheumatology. Labial salivary gland (LSG) samples
were obtained from patients with SS and controls. The degree of
lymphocytic infiltration in the specimens was determined using
a modification of the system originally introduced by Greenspan
(23). The results are classified into five grades in a blind manner
by three pathologists: Grade 0= the absence of lymphocytes and
plasma cells per 4 mm2 in LSGs, Grade 1 = mild infiltration of
lymphocytes and plasma cells per 4 mm2 in LSGs, Grade 2 = a
moderate infiltration or less than one focus per 4 mm2 in LSGs,
Grade 3 = a single focus per 4 mm2 in LSGs, and Grade 4 =
more than one focus per 4 mm2 in LSGs. One focus refers to
an aggregate of ≧50 mononuclear cells, including lymphocytes,
histiocytes, and plasma cells around the ductal structure. Five
to seven samples per group were used for analysis. Control
samples were collected from non-inflamed tissues of patients
with mucous cyst or other oral disorders.
Statistical Analysis
Differences between individual groups were determined using
two-tailed Student’s t-test or betweenmore than two groups using
one-way ANOVA with Turkey’s multiple comparison post-test. p
< 0.05 was considered statistically significant. Power calculations
were performed before the beginning of the experiments to
determine the sample size for experiments using human samples
or animals. Data are presented as mean± standard error of mean
(SEM).
Data Availability
The PCR array data are available from the Gene Expression
Omnibus database under accession number GSE110816.
RESULTS
M8s in the Salivary Gland of the SS Model
Mouse
We have established a mouse model of SS wherein NFS/sld mice
are thymectomized on day 3 after birth (24, 25). The autoimmune
lesions in the salivary and lacrimal glands are observed from 6
weeks of age (24). The main subset of immune cells infiltrated
in the target organ of the SS model mice at 6 weeks of age
is CD4+ T cells; small populations of CD8+ T cells, B cells,
macrophages (M8s), and dendritic cells are also observed (26).
The proportion of infiltrated immune cells in the target organ
changes with age. At 8 weeks of age, the autoimmune lesions
are observed in almost 100% of the SS model mice (24). Female
mice exhibit faster onset of disease andmore severe inflammatory
lesions compared with male mice. In addition, autoantibodies
such as anti-SSA, anti-SSB, and anti-α-fodrin were detected in
the SS model (24, 25). We compared the distribution of M8s
in the salivary glands (sM8s) of control and SS model mice.
Immunohistochemical analysis revealed sporadic F4/80+ M8s
around ductal, acinar cells and small vessels in the control mice
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FIGURE 1 | Salivary gland macrophages (sM8s) of the SS model mice. (A) Immunohistochemical analysis of F4/80+ macrophages in the salivary gland sections
obtained from the controls and SS models at 8 weeks of age. Photos are representative of 5 mice in each group. Scale bar: 50µm (B) CD11bhigh and CD11blow
F4/80+ sM8s in the controls and SS models. (C) Total number of F4/80+ sMφs in the controls and SS models from 8 to 20 weeks of age. Bilateral whole salivary
gland lobes per mouse were minced and enzymatically digested. Mononuclear cells were enriched using a Histopaque-1083. Cell number was determined by cell
counter using trypan blue staining and flow cytometer with antibodies for specific markers. (D) Number of CD11blow F4/80+ sM8s in the controls and SS models
from 8 to 20 weeks of age. **p < 0.005 by Student’s t-test. (E) CD11bhigh F4/80+ sM8s in the controls and SS models from 8 to 20 weeks of age. Data are
presented as the mean ± SEM. *p < 0.05 by Student’s t-test. n = 5–10 (C–E).
(Figure 1A). By contrast, many F4/80+ M8s were observed
surrounding the autoimmune lesions in the SS model mice at 8
weeks of age (Figure 1A).
Next, the surface markers on sM8s were analyzed using
flow cytometry. CD45.2+ CD3− CD19−-gated monocytes
(Supplemental Figure 1) were examined for CD11b and F4/80
expression (Figure 1B). Two subsets that displayed CD11bhigh
F4/80+ and CD11blow F4/80+ M8s were detected in the salivary
glands (Figure 1B). These two subsets were evaluated using
control and SS model mice from 8 to 20 weeks of age. At 8
weeks of age, the number of F4/80+ CD11b+ sM8s in the SS
model mice was significantly higher than that in control mice
(Figure 1C). Although the cell numbers in both the control and
SS model mice increased with age, there was no difference in
the number between control and SS model from 12 to 20 weeks
of age (Figure 1C). At 8 weeks of age, the number of CD11blow
F4/80+ sM8s in the SS model mice was significantly higher than
that in the control mice; however, no changes were observed
between the control and SS model mice from 12 to 20 weeks of
age (Figure 1D). In contrast, the number of CD11bhigh F4/80+
sM8s in the SS model mice aged between 12 and 16 weeks was
significantly higher than that in the control mice (Figure 1E). At
20 weeks, there was no difference in the number of CD11bhigh
F4/80+ sM8s between control and SS model mice (Figure 1E).
These findings indicate the existence of CD11bhigh and CD11blow
F4/80+ sM8 subsets; these two subsets may play a role in the
onset or development of autoimmune lesions in the target organs
of SS model mice.
Phenotype and Function of Two M8
Subsets in Salivary Glands
To define the difference between the cell surface phenotypes
of the two subsets in the salivary glands, key M8 markers
were analyzed using flow cytometry. No significant differences
were observed between the control and SS model mice at 12
weeks of age with respect to any of the markers of two subsets
(Figure 2A). Among M1 M8 markers, including CCR2, MHC
class II, CD11c, and CD86, the expressions of MHC class II,
CD11c, and CD86 on CD11bhigh F4/80+ sM8s were higher than
those on CD11blow F4/80+ sM8s (Figure 2A). The expression
pattern of CCR2 and CX3CR1 expression on CD11bhigh F4/80+
sM8s suggested that a fraction of these cells carried the
chemokine receptor including CCR2 or CX3CR1, whereas the
other fraction did not (Figures 2A,B). Expression of CD206 (a
M2 and tissue-resident M8marker) on CD11bhighF4/80+ sM8s
was enhanced compared with that on CD11blowF4/80+ sM8s
(Figure 2B). In addition, the expressions of CD204 and CD36
(scavenger receptors) on CD11bhigh F4/80+ sM8s in the SS
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FIGURE 2 | Phenotypes and functionality of tissue-resident M8s in salivary glands of controls and SS models. (A,B) Key surface markers on CD11bhigh and
CD11blow sM8s of control and SS model mice were detected using flow cytometry. Data are representative of 5 mice in each group at 12 weeks of age.
(C) Phagocytic activity of CD11bhigh and CD11blow sM8s of control and SS model mice at 12 weeks of age was determined by in vitro assay with FITC-conjugated
beads. Data are representative of three independent experiments. Gray shadow: 4◦C culture. (D) Phagocytic activity is shown as mean ± SEM. n = 4–6 per group.
*p < 0.05 by Student’s t-test.
model were higher than the control mice (Figure 2B). These
findings indicate that CD11blow F4/80+ sM8s are M1-like M8
whereas CD11bhigh F4/80+ sM8s are similar to the phenotype
of M2-like and tissue resident-like M8s. However, it is possible
that the sM8s may differentiate into the phenotype or function
independent of their differentiation into M1 and M2 M8s.
To evaluate the in vitro phagocytic activity of the two
subsets, sM8s of the control and SS model mice were
analyzed using FITC-labeled latex beads. With respect to the
phagocytic activity of CD11high F4/80+ sM8s, no significant
differences were observed between the control and SS model
mice (Figures 2C,D). There was no difference in the phagocytic
activity of CD11blow F4/80+ sM8s between the SS model and
control mice (Figures 2C,D). Contrarily, in both control and
SS model mice, the phagocytic activity of CD11high F4/80+
sM8s was significantly higher than that of the CD11blow
F4/80+ sM8s (Figures 2C,D). These findings indicate that the
two subsets of M8s in the salivary gland are functionally
distinct.
Chemokine Expression of CD11bhigh
F4/80+ sM8s in the SS Model Mice
Next, to define the role of the two subsets of sM8s in the
formation of autoimmune lesions, we focused on chemokine
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gene expression of sM8s of the SS model mice. Using PCR-
array, we comprehensively compared chemokine mRNA gene
expression between CD11bhigh and CD11blow F4/80+ sM8s in
the SS model mice (Figure 3A). Relative to that of CD11blow
sM8s, over 50-fold increase was observed in the mRNA
expression of CD11bhigh sM8s; this increase was observed in
several genes, such as CCL7, CXCL2, CCL6, CCL8, CXCL13,
and CCL22 (Figure 3B). Among these, CCL22mRNA expression
level of CD11bhigh sM8s was over 150-times higher than that of
CD11blow sM8s (Figure 3B). In addition, quantitative RT-PCR
assay revealed that CCL22 mRNA level was significantly higher
in salivary gland tissues of the SS model mice than of the control
mice (Figure 3C). Moreover, the CCL22 mRNA level was also
significantly higher in lung tissues of the SS model mice than
of the control mice (Figure 3C). In addition, intracellular flow
cytometric analysis revealed significantly higher expression of
CCL22 in the sM8s in the SSmodel mice than in the control mice
(Figure 3D). Furthermore, CD11bhigh F4/80+ but not CD11blow
F4/80+ sM8s strongly expressed CCL22 in the SS model
mice (Figure 3E). Moreover, CCL22-producing F4/80+ sM8s
were observed in the SS model mice by confocal microscopic
analysis (Figure 3F). By contrast, confocal microscopic analysis
indicated that EpCAM+ epithelial cells, CD3+ T cells, CD19+
B cells, and CD11c+ DCs did not express CCL22 (Figure 3G).
Immunohistochemical analysis showed that interstitial cells such
as fibroblasts, endothelial cells, and nerve cells did not also
express CCL22 (Figure 3H). The results suggest that CCL22-
producing sM8s may play a potent role in the pathogenesis of
SS.
Contribution of CCL22 to Migration and
Cytokine Production of T Cells
We evaluated the expression of CCR4 (a receptor of CCL22)
in the lymphoid organs and the target organs of control and
the SS model mice. The expression level of CCR4 mRNA was
significantly higher in the salivary glands of the SS model mice
than of the control mice (Figure 4A). The expression in the
salivary glands of SS model mice was considerably higher than
that of the spleen (Sp), lung, and liver (Figure 4A). Furthermore,
the expression of CCR4 on CD4+ T cells in spleen, cervical
lymph node (cLN), and salivary glands was assessed using
flow cytometry. The proportion of CCR4+ CD4+ T cells was
significantly higher in the salivary glands than in the spleen
and cLN of the SS model mice (Figure 4B). There was no
significant difference in the proportion of CCR4+ CD4+ T
cells between spleen and cLN in control mice (Figure 4B).
We analyzed the mRNA expressions of the other chemokine
receptors, such as CXCR3A, CCR3, and CX3CR1 mRNA in
the salivary gland tissues of control and SS model mice.
CXCR3A mRNA expression in the salivary gland tissues from
SS model mice was significantly higher than that in the salivary
gland tissues from control mice (Supplemental Figure 2A). In
addition to CXCR4, other chemokine receptors may affect the
pathogenesis of SS. Next, an in vitro migration assay was
performed using CD4+ T cells purified from spleen cells to
evaluate the migratory activity of T cells toward CCL22. The
migratory activity of CD4+ T cells purified from the spleen
of the SS model mice was significantly higher than that of
CD4+ T cells purified from the spleen of the control mice
(Figure 4C, Supplemental Figure 2B). These findings indicate
that T cell migration is controlled by CCL22 in the SS model
mice.
CCL22 also plays a key role in T cell differentiation in
addition to T cell migratory activity (27). In this SS mouse
model, Th1 cells that produce IFN-γ contribute to the
pathogenesis of autoimmune lesions in the target organ
(24) (Supplemental Figure 3A). Splenic CD4+ T cells from
the control and SS model mice were cultured with CCL22 for
6 h; mRNA expression of cytokines, including IFN-γ , IL-4,
and IL-17, was then determined by qRT-PCR. IFN-γ mRNA
expression of CD4+ T cells purified from the spleen of the SS
model mice was significantly enhanced in response to CCL22
(Figure 4D). IL-17 mRNA of splenic CD4+ T cells in the
control mice was significantly enhanced in response to CCL22,
whereas no change was observed in IFN-γ and IL-4 mRNA
(Supplemental Figure 3B). Further, besides up-regulated IFN-γ
mRNA, IL-17 mRNA of CD4+ T cells from the cLN in the SS
model mice was significantly increased in response to CCL22
(Figure 4D). Finally, mRNA expressions of all cytokines in
CD4+ T cells obtained from the salivary glands of the SS
model mice were significantly increased in response to CCL22
(Figure 4D). Moreover, to examine whether CCL22 influences
the cytokine secretion by T cells, concentrations of IFN-γ,
IL-4, and IL-17 were analyzed using the culture supernatant
of anti-CD3/CD28-stimulated CD4+ T cells isolated from
the salivary gland tissues of SS model mice. Concentrations
of IFN-γ and IL-4 were significantly enhanced by CCL22,
whereas no changes were observed in IL-17 level (Figure 4E).
In addition, to examine the protein level of cytokine production
by CCL22, intracellular expressions of IFN-γ, IL-4, and IL-17
in the presence of CCL22 were analyzed using anti-CD3/CD28-
stimulated CD4+ T cells from spleen of control and SS model
mice. IFN-γ expression in CD4+ T cells of SS model mice was
significantly enhanced by CCL22, whereas there were no changes
in IL-4 and IL-17 expressions (Supplemental Figures 3C,D).
These findings indicate that CCL22 may disturb the
regulation of IFN-γ production by T cells in the target
organ.
Therapeutic Effect of Anti-CCL22 Antibody
(Ab) Administration on Autoimmune
Lesions in the SS Model
SS model mice were administered with anti-CCL22 Ab from 8 to
10 weeks of age to determine the effect of CCL22 inhibition on
autoimmune lesions. Anti-CCL22 Ab (4 µg) was intravenously
injected into a mouse on alternate days for 2 weeks (Figure 5A).
After treatment with anti-CCL22 Ab, the number of F4/80+
CD11b+ total sM8s in salivary glands of SS model mice was
significantly decreased compared with that of SS model mice
treated with control IgG (Figure 5B). Furthermore, the number
of both macrophages, CD11bhigh and CD11blow F4/80+ sM8s,
in salivary glands of anti-CCL22-treated mice was significantly
decreased compared with that of control IgG-treated SS model
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FIGURE 3 | Comprehensive analysis of chemokine genes of sM8s. (A,B) Chemokine mRNA expressions of isolated CD11bhigh and CD11blow sM8s of the SS
model mice at 12 weeks of age were analyzed using PCR-array. Up-and downregulated genes of CD11bhigh sM8s compared with CD11blow sM8s of the SS model
mice. The lines indicate 5-fold change in the gene expression. Red dots are upregulated genes, and blue dots are downregulated genes. Data are representative of
three independent experiments. (C) CCL22 mRNA expression levels of various tissues of the SS model and control mice at 12 weeks of age were determined
using qRT-PCR. Data are presented as mean± SEM. *p< 0.05 by Student’s t-test. n= 5. (D)CCL22 expression of sM8s in salivary glands of control and SSmodel mice
(Continued).
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FIGURE 3 | (left). CCL22 positive cell number (right). Data are representative of five mice in each group and are presented as mean ± SEM. ***p < 0.0005 by Student’s
t-test. n = 5. Gray shadow is isotype control. (E) Comparison of CCL22 expression between CD11bhigh and CD11blow sM8s of the SS model mice at 12 weeks of
age. Data are representative of five mice. Gray shadow is isotype control. (F) CCL22-producing sM8s of the SS model mice were detected by confocal microscopic
analysis. Data are representative of five mice. (G) Confocal microscopic analysis of CCL22 expression of EpCAM+ epithelial cells, CD3+ T cells, CD19+ B cells, and
CD11c+ DCs in the salivary gland tissues form SS model mice. Data are representative of three mice. Nuclei were stained with DAPI. (H) Immunohistochenical
analysis of CCL22 expression using the salivary gland tissues from SS model mice. The result is representative of three mice. Nuclei were stained with hematoxylin.
mice (Figure 5C), suggesting that other cells would be activated
by secreting CCL22. Pathological examination revealed that
when compared with the effect of isotype control Ab on
SS model mice, anti-CCL22 Ab considerably suppressed the
inflammatory lesions in the salivary glands of the SS model
mice (Figure 5D). The number of lymphocytes infiltrated in
the salivary gland tissue (/4 mm2) was significantly lower in
the anti-CCL22 Ab-treated mice than in the control isotype
antibody-treated mice (Figure 5E). In addition, flow cytometric
analysis revealed that the number of CD4+ cells that had
infiltrated in the salivary glands was significantly lower in the
SS model mice injected with anti-CCL22 Ab was significantly
decreased compared with that of SS model mice injected with
isotype control Ab (Figures 5F,G). As for CD8+ T cells, the
decrease of the proportion and the cell number was observed
in anti-CCL22 Ab-treated mice (Figures 5F,G). These results
suggest that CCL22-producing sM8s may serve as a target for
treating SS.
Detection of CCL22-Producing sM8s in
Patients With SS
To determine whether the CCL22-producing sM8s contribute to
autoimmune lesions in patients with SS, immunohistochemical
analysis was performed with anti-CCL22 Ab using minor
salivary gland tissues obtained from controls and patients
with SS. Based on the degree of lymphocyte infiltration, tissue
sections of lip biopsy specimens were divided into four grades
(23, 28). Numerous CCL22-producing cells were detected in
the high-grade biopsy sections (Figure 6A). Pathological grade
and the number of CCL22-producing cells were significantly
correlated (Figure 6B). The histopathological criterion of SS
diagnosis was a focus score ≧1 which includes Grade 3 and 4
(23). Compared with patients with a focus score< 1, the number
of CCL22+ cells was significantly higher in the salivary gland
tissues from patients with SS with a focus score ≧1 (Figure 6C).
In addition, confocal microscopy revealed many CCL22-
producing CD68+ sM8s in the minor salivary gland tissues
from patients with SS (Grade 4); however, only few CCL22+
sM8s were detected in controls (Figure 6D). In addition,
CCL22 was not expressed in stromal cells, such as fibroblasts,
endothelial cells, and nerve cells (Supplemental Figure 4A).
Furthermore, confocal microscopic analysis confirme
that Keratin+ epithelial cells (Supplemental Figure 4B),
CD3+ T cells (Supplemental Figure 4C), CD19+
B cells (Supplemental Figure 4D), and S100+ DCs
(Supplemental Figure 4E) did not express CCL22. A previous
report indicated that CCL22 is secreted by macrophages
or DCs in vitro and in vivo (29). This result indicates that
CCL22-producing sM8s play a key role in the formation
of autoimmune lesions in the target organ of patients
with SS.
DISCUSSION
In the current study, we investigated the relationship between
autoimmunity and M8s in the target organs in the SS mouse
model and the patient with SS. Resident M8s were divided
into two subsets that displayed low and high expression
levels of CD11b in the SS model mice. Via the control of
T cell migration and cytokine production, CCL22-producing
CD11bhigh macrophages play a key role in the development of
autoimmune lesions in the salivary glands.
The number of M8s in the salivary glands was significantly
higher in the SS model mice than in the control mice at 8
weeks of age; however, no difference was observed in the respect
at the subsequent time-point. The number of CD11blow sM8s
also significantly increased at 8 weeks of age, which is the stage
of onset of autoimmune lesions in the model. In contrast, the
number of CD11bhigh sM8s was significantly higher in the SS
model mice than in the control mice between 12 and 16 weeks
of age, which corresponds to the stage wherein development of
autoimmune lesions occurs in the SS model mice. These results
suggest that the phenotypic change to CD11bhigh sM8s within
the target organ may be induced during the development of
autoimmune lesions. In addition, it is possible that bonemarrow-
derived myeloid cells may accumulate to become M8s in the
target organ.
During various inflammatory processes, naïve monocytes
differentiate into pro-inflammatory M1 and anti-inflammatory
M2 M8s (30, 31). The diverse phenotypes and functionality of
resident M8 in different organs is well-documented (32, 33). It is
difficult to differentiate between the M1 andM2 subsets based on
the surface markers (34). No differences were observed between
the control mice and SS model mice with respect to M1/M2
markers. However, expressions of scavenger receptors (CD36 and
CD204) on CD11blow sM8s of the SS model mice were clearly
enhanced. Phagocytic activity of both CD11blow and CD11bhigh
sM8s in the SS model mice was also upregulated. These results
indicate that the phenotypic difference between CD11blow and
CD11bhigh does not contribute to the differentiation into M1/M2
M8 subsets and the phagocytic function of M8. On the other
hand, it is possible that CD11blow sM8s may play a role in the
pathogenesis of the SS model mice. As shown in Figure 1, the
number of CD11blow sM8s in SS model mice at 8 weeks of age
was significantly higher than that in control mice; therefore, the
CD11blow sM8s may contribute to the onset or early stage of the
disease. However, further study is required for a detailed analysis
of this population in detail in the next project.
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FIGURE 4 | CCR4 expression on peripheral T cells and migratory activity of T
cell by CCL22. (A) CCR4 mRNA expression levels in tissues were determined
by qRT-PCR. Data are presented as mean ± SEM. n = 5. (B) CCR4
expression on CD4+ T cells purified form the spleen (Sp), cLN, and salivary
glands (Sg) of SS model mice at 12 weeks of age was determined by flow
cytometric analysis. Data are representative of five mice, and mean ± SEM of
CCR4+ cells (%) of CD4+ T cells. Gray shadow is isotype control. **p <
0.005, ***p < 0.0005 by one-way ANOVA with Turkey’s multiple comparison
post-test. UD, undetermined. (C) Migratory activity of CD4+ T cells from SS
model mice to CCL22 (200 ng/mL) was analyzed by in vitro migration assay
using trans-well. Data are representative of three independent experiments. *p
< 0.05 by Student’s t-test. (D) CD4+ T cells purified from the spleen, cLNs,
and salivary glands in SS model mice at 12 weeks of age were cultured with
CCL22 for 6 h. The mRNA expressions of IFN-γ, IL-4, and IL-17 were detected
by qRT-PCR. Data are presented as mean ± SEM relative to that without
CCL22 and are representative of three independent experiments. *p < 0.05,
**p < 0.005 by Student’s t-test. (E) CD4+ T cells isolated from salivary gland
tissues of SS model mice were cultured with or without CCL22 (200 ng/mL) in
the presence of anti-CD3/CD28 mAb-beads for 48 h, and subsequently
cultured with PMA (50 ng/mL) and iomomycin (IM) (1µg/mL) for the last 6 h.
Cytokine levels, including IFN-γ, IL-4, and IL-17, in the supernatant were
measured using a Cytokine 20-Plex Mouse Panel Luminex assay kit. Data are
expressed as the mean concentration pg/mL) ± SEM, n = 4 per group. *p <
0.05 by Student’s t-test.
We have checked many markers of macrophage in
preliminary experiments before focusing on CD11b expression.
Among these, we found that CD11b expression in the target
tissue of SS model mice changed with disease progression in the
SS model mice. Therefore, we decided to focus on the analysis of
the role or function of CD11blow/high sM8s in the target tissues
at the onset or development of the disease.
To determine a key molecule for the development of
autoimmune disease in the SS model mice, experiments were
conducted in two steps. The first step was comprehensive
gene analysis limiting chemokine genes to compare the gene
expression of CD11bhigh sM8s with that of CD11blow sM8s
in the SS model mice. In the second step, several genes among
the upregulated genes that showed a significant difference
between the control and SS model mice were picked up.
Among these, the CCL22 gene of CD11bhigh sM8s was
selected as a potential candidate that plays a key role in the
development of autoimmune lesions. Alongside the development
of autoimmune lesions, CCL22-producing CD11bhigh sM8s
were increased in SS model mice. M2a, a subset of M2 M8,
induced by IL-4 and IL-13 exposure expresses arginase I and
produces CCL22, IL-10, TGF-β, IL-1Ra, CCL17, and CCL24
to promote Th2 cells, eosinophils, and basophils (1–4, 6). The
CCL22-producing sM8s seem to differ from the M2a M8
subset.
CCL22 is one of the C-C motif chemokines and is termed
as M8-derived chemokine (MDC) in humans and mice. CCL22
and CCL17 bind to CCR4, and both chemokines are 39%
identical at the amino acid level (34). Both CCL22 and CCL17
are highly expressed in the thymus (35, 36). The role of CCL22
in peripheral T cells is not clear. IFN-γ-producing Th1 cells were
shown to contribute to the onset of autoimmune lesions in the
SS model mice (24). In the present study, cytokine production
in CD4+ T cell response to CCL22 showed differences between
the spleen, cLN, and target tissue in the SS model mice. It
is possible that the differences regarding receptor expression
may be related to the cytokine production through different
signaling of the T cells. Hence, CCL22 may play a key role in
the breakdown of local immune tolerance in the target organ to
induce autoimmune lesions in SS. In addition, our hypothesis is
that CCL22 from CD11bhigh sM8s may enhance the migration
of effector T cells into the target organ through CCR4 on T
cells and also the cytokine production, such as IFN-γ, by T
cells. In addition, the mRNA expressions of IFN-γ , IL-4, and
IL-17 in T cells isolated from the salivary gland tissues of SS
model mice were enhanced by CCL22. IFN-γ and IL-4 protein
secretion was also enhanced by CCL22. As for the discrepancy
in IL-17 between the mRNA and protein expressions of IL-
17, protein secretion of IL-17 may be influenced by any other
factor. Previous reports demonstrate that CCR4 is predominantly
expressed by Th2 cells, cutaneous lymphocyte antigen-positive
skin-homing T cells, and Treg cells (36, 37). Therefore, CCL22
is considered one of the Th2-associated chemokines (38, 39).
Our result was consistent with the elevated CCL22 in salivary
gland tissues from patients with SS as described previously
(40). The high expression level of CCR4 on CD4+ T cells that
infiltrate the target organ is a novel finding that highlights the
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FIGURE 5 | Therapeutic effect of anti-CCL22 Ab administration on autoimmune lesions in SS model mice. (A) Experimental schedule. Anti-CCL22 Ab (4 µg) was
intravenously injected into a mouse on alternate days for 2 weeks. (B) Total number of sM8s infiltrated in the salivary gland tissues from control IgG and anti-CCL22
Ab treatment was determined by cell counter and flow cytometry. (C) The number of CD11blow/high sM8s in the salivary gland tissues was determined using cell
counter and flow cytometry. (D) Pathological analysis was performed using H&E-stained sections of salivary gland tissues from the SS model mice administered with
anti-CCL22 Ab and isotype control antibody. Data are representative of five mice in each group. (E) Number of lymphocytes infiltrated into salivary gland tissues within
2 × 2 mm2 was counted using H&E-stained sections. (F) CD4/CD8T cell phenotype in the salivary gland tissues was analyzed by flow cytometry. Data are
representative of five mice in each group. (G) The number of CD4+ (left) and CD8+ T cells in the salivary gland tissues was determined using cell counter and flow
cytometry. Data are presented as mean ± SEM of five mice (B, C, E, and G). *p < 0.05 **p < 0.005 by Student’s t-test.
key role of the CCL22-CCR4 axis in the autoimmune reaction
in the target organ. Previously, CCL22 was detected around the
ductal epithelial cells, whereas CCR4 was detected on infiltrating
lymphocytes in the minor salivary glands of patients with SS.
From our study, any subset of sM8s may be the source of CCL22
in the target organ of SS. Th1 and Th17 cells may be involved
in the initiation of SS, and Th2 cells may contribute to disease
progression through the interaction between chemokines and
chemokine receptors, such as CCL22 and CCR4. In contrast,
although it was reported that CCL22 gene expression of minor
salivary glands of patients with SS was less pronounced (20), our
study demonstrated that a part of macrophage subsets highly
produces CCL22 in the target tissue in SS. Therefore, it is
possible that the increased gene expression of CCL22 in the whole
tissue cannot be observed. We determined the concentration of
CCL22 for in vitro migration assay based on a previous report
(41) and our preliminary experiment (Supplemental Figure 2).
Indeed, 200 ng/mL of CCL22 may be much higher than the
physiological concentration. However, it is difficult to determine
the physiological or pathological concentration in vivo, and the
concentration gradient may change with disease progression in
the SS model mice.
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FIGURE 6 | CCL22-producing sM8s of minor salivary gland tissue from patients with SS. (A) CCL22+ cells from the minor salivary gland tissues from controls and
patients with SS were detected by immunohistochemical analysis. Sections of controls and patients with SS (Grade 1 to 4) were used for analysis. Photos are
representative of 5–7 samples in each group. (B) The number of CCL22+ cells was determined, and data are presented as mean ± SEM of five samples. *p < 0.05,
**p < 0.005 by one-way ANOVA with Turkey’s multiple comparison post-test. (C) Correlation in CCL22+ cells between focus score 1 < and 1≧ patients. The number
of CCL22+ cells was determined, and data are presented as mean ± SEM of five samples. *p < 0.05, **p < 0.005 by Student’s t-test. (D) CCL22-producing CD68+
sM8s were detected by confocal analysis using the section of controls and SS patients (Grade 4). Photos are representative of 5 samples in each group. Bar: 50µm.
In the current study, anti-CCL22 Ab has a therapeutic
effect on the autoimmune lesions in the SS model mice. A
previous report demonstrated that CCL22 regulates experimental
autoimmune encephalaomyelitis (EAE) via the control of M8
chemoattraction and effector function (27, 42, 43). CCR4 is
also known to play a potent role in the development of
EAE (44, 45). Furthermore, a CCR4 antagonist was shown
to ameliorate EAE via the inhibition of Th1 and Th17
polarization of antigen-induced T cell response (46, 47). In
contrast, CCL22-mediated recruitment of Treg cells to the
pancreas protects against autoimmune diabetes in a murine type
1 diabetes model (48, 49). CCL22 has also been implicated
in various diseases, including allergic disease, and lymphoma
(50–54). CCL22 and its receptor contribute to the onset
or development of immune disorders by inducing changes
in the expression and contribution or the functions (55,
56). In our model, CD11bhigh sM8s intensively produced
CCL22 to influence T cell responses in the target tissue. In
addition, as the infiltration of CD8+ T cells in the salivary
gland tissues was also suppressed by the injection of anti-
CCL22 Ab, the same mechanism may apply for CD8+ T
cell migration to the target organ. A large number of CD8+
T cells were accumulated in the salivary gland tissue of SS
model mice (Figure 5D). As mentioned, CD4+ T cells are
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the main subset of immune cells infiltrated in the salivary
gland in this model in the early stage. As shown in Figure 5,
we analyzed the mice at 10 weeks of age, when CD8+ T
cells also are infiltrated in addition to the other immune cell
populations.
We analyzed the cytokine mRNA expression of cultured T
cells in vitro to examine the direct effect of CCL22 on T cells.
It is important to detect cytokine expression directly in the
target tissues. However, it is difficult to assess the effect of
CCL22 on the cytokine expression of T cells in vivo. Analysis
of CD11b-conditional CCL22 gene knockout mouse in the
next study will help define the in vivo function of CCL22 in
autoimmunity.
In this study, in addition to CCL22 gene, several
chemokine genes of CD11bhigh sM8s were upregulated,
suggesting that complicated chemokine network by resident
M8s with phenotypic change affects the pathogenesis of
autoimmune lesions. Moreover, CCL22 gene expression
of lung in the SS model mice was significantly higher
than that of control mice. As slight inflammatory lesions
of the lung in the SS model mice are observed with
age, CCL22 may play a key role in the pulmonary
lesions.
To summarize, a phenotypic change in the resident sM8s
of SS model mice was observed during the development of
autoimmune lesions. CCL22-producing resident M8s influence
T cell migration and cytokine production in the target organ of
the SS model mice. Interventions that target M8s may serve as a
potential novel treatment for autoimmune diseases.
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Supplemental Figure 1 | Gating strategy and representative gating of immune
cells obtained from salivary gland tissues in the SS models. FSC-A/SSC-A,
FSC-A/FSC-H, and FSC/CD45.2 panels are shown. After gating single cells and
CD45.2+ cells among live cells, 7-AAD−CD3−CD19− cells were gated for
obtaining M8 population.
Supplemental Figure 2 | (A) mRNA expressions of CXCR3A, CCR3, and
CX3CR1 in salivary gland tissues from control and SS model mice at 12 weeks of
age were determined by qRT-PCR. Data are presented as mean ± SEM. n = 5.
The primer sequences used were as follows: CXCR3A: forward,
5′-TGCTAGATGCCTCGGACTTT-3′, and reverse, 5′- CGCTGACTCAGT
AGCACAGC-3′, CCR3: forward, 5′-TTGATCCTCATAAAGTACAGGAAGC-3′, and
reverse, 5′- CAATGCTGCCAGTCCTGCAA-3′, CX3CR1: forward, 5′-
CACCATTAGTCTGGGCGTCT-3′, and reverse, 5′- GATGCGGAAGTAG
CAAAAGC-3′. Relative mRNA expression of each transcript was normalized
against β-actin mRNA. (B) Migratory activity of CD4+ T cells from SS model mice
to CCL22 (0, 50, 100, and 200 ng/mL) was analyzed by in vitro migration assay
using trans-well. Data are representative of three independent experiments. ∗p <
0.05 by Student’s t-test.
Supplemental Figure 3 | (A) Intracellular expressions of IFN-γ, IL-4, and IL-17 of
activated splenic CD4+ T cells. CD4+ T cells purified from spleen of the control
and SS model mice were stimulated with PMA (50 ng/mL) and ionomycin
(1µg/ml) for 6 h with Golgi-stop. Data are representative of three independent
experiments. (B) CD4+ T cells purified from the spleen in control mice were
cultured with CCL22 (200 ng/mL) for 6 h. The mRNA expressions of IFN-γ, IL-4,
and IL-17 were detected by qRT-PCR. Data are presented as mean ± SEM
relative to that without CCL22 and are representative of three independent
experiments. ∗p < 0.05 by Student’s t-test. (C) Intracellular IFN-γ expression in
CD4+ T cells of SS model mice. CD4+ T cells were stimulated with or without
CCL22 (200 ng/mL) in the presence of anti-CD3/CD28 mAb for 48 h, and were
subsequently cultured with PMA (50 ng/mL) and IM (1µg/mL) in the presence of
Brefeldin A for the last 6 h. The results are representative of five samples in each
group. (D) Intracellular cytokine expressions of IFN-γ, IL-4, and IL-17 in splenic
CD4+ T cells of control and SS model mice were analyzed by flow cytometer.
Data are presented as mean ± SEM relative to that without CCL22. n = 5. ∗p <
0.05 by Student’s t-test, ∗∗p < 0.005 by Student’s t-test.
Supplemental Figure 4 | (A) Stromal cells did not express CCL22. CCL22 was
detected by immunohistochemical analysis. Bar: 500 and 50µm. (B–E) Confocal
microscopic analysis of CCL22 expression of Keratin+ epithelial cells (B), CD3+ T
cells (C), CD19+ B cells (D), and S100+ DCs (E) using the sections of SS patients
(Grade 4). Photos are representative of five samples in each group. Bar: 50µm.
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